Mastodon
Kliniken &… Kliniken Medizinische… Klinische Pharmakologie… Klinische Studien Aktuelle Studien

Aktuelle Studien Abteilung Klinische Pharmakologie

Im Heidelberger Klinisch-Pharmakologischen Studienzentrum wird ein breites Spektrum von gesunden Probanden:innen bis hin zu schwer erkrankten Patient:innen betreut. Wir führen sowohl eigeninitiierte, als auch industriegesponserte Studien, vornehmlich der frühen Phasen, durch.

  • Sie interessieren sich für eine Studienteilnahme als gesunder Freiwilliger? Hier finden Sie relevante Informationen.
  • Sie sind Patient und sollen in unserem Klinisch-Pharmakologischen Studienzentrum behandelt werden? Erste Informationen erhalten Sie hier
  • Sie kommen aus der akademischen Forschung oder Industrie und möchten Ihre Studie in unserem Studienzentrum durchführen lassen? Informieren Sie sich auf unserer Seite für Sponsoren

Studienteilnehmer:innen gesucht!

Eine Übersicht der Studien, für die wir aktuell (gesunde) Studienteilnehmer:innen suchen, finden Sie hier. 

Kooperationsstudien am Universitätsklinikum Heidelberg

Des Weiteren werden auch Studien in Kooperation mit anderen Fachabteilungen und Partnern am Universitätsklinikum Heidelberg durchgeführt.

Hierzu gehören unter anderem:

Studien mit pädiatrischen Patienten oder vornehmlich pneumologischer Indikation (u. a. auch Studien nach dem Medizinproduktegesetz) werden bei unseren Netzwerk-Partnern, dem pädiatrischen klinisch-pharmakologischen-Studienzentrum (paedKliPS) und dem pneumologischen klinisch-pharmakologischen Studienzentrum (ThoraxKliPS) durchgeführt.

Laufende Studien

Im Folgenden finden Sie eine Übersicht aller aktuell laufenden Studien.

EudraCT - NUMMERKURZTITELDESIGN
freie StudieGenotype - BiobankDNA Biobank for Genotype Screening of Volunteers for the 
Participation in Clinical Studies
2017‐003448‐19/2023-506564-14CC-93269-MM-001 (Engmab)Phase 1, open-label, dose finding study of  CC-93269, A BCMA X CD3 T cell engaging antibody, in subjects with relapsed and refractory multiple myeloma
2021-002584-22PANHPVAXfirst-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP
2019-001213-17Myr301A Multicenter, Open-label, Randomized Phase 3 Clinical Sudy to Assess Efficacy and Safety of bulevirtide in Patients with Chronic Hepatitis Delta 
2018-004767-31CC92480-MM-002Phase 1/2 multicenter, open-label, study to determine the recommended dose and regimen, and evaluate the safety and preliminary efficacy of CC-92480 in combination with standrad treatments in subjcets with  with relapsed and refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM)
2019-001932-80NI006-StudieA Phase I, First in Human, Double-Blind, Placebo-Controlled, Multicenter, Single and Multiple Ascending Dose Study of NI006 in Patients with Amyloid Transthyretin Cardiomyopathy followed by an Open-Label-Extension
2019-001743-48WVT078A Phase I, open-label, multicenter, study of WVT078 in subjects with relapsed and/or refractory multiple myeloma
2019-000330-19TRIMM 2Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
2018-004154-25Panorama -OLE
PK015
A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319
2017-002400-26TalmmyA Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
2022-001096-13BempedoinsäureEffect of staggered vs. simultaneous open-label administration on the pharmacokinetics of pravastatin and bempedoic acid in healthy volunteers
2020-003414-12Heidelberg PharmaA Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
2018-004354-21DREAMM8A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)
freie StudieHealthy VolScreening von gesunden Freiwilligen: Evaluation und Optimierung eines Schlüsselprozesses für Klinische Prüfungen der Phase 0/I
2022-000928-37MajesTec-9A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
2022-003679-40HelicasePhase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of single doses of IM-250 in healthy volunteers
2021-005073-22TRIMM-3Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma
2020-000384-23BI 764198A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis.
2021-006226-49NN6019Efficacy and safety of NNC6019-0001 at two dose levels in participants with
transthyretin amyloid cardiomyopathy (ATTR CM)
2023-504405-37-00TacroBiomAssessment of the influence of the gut microbiome on tacrolimus pharmacokinetics in healthy volunteers
compassionate useTecli CompassionateNamed Patient Program (NPP) 64007957MMY4001 PRE-APPROVAL ACCESS (PAA) for Teclistamab (JNJ-64007957)
2022-000261-40NUC-011/BIOPharmacokinetic (PK) study to investigate the pharmacokinetic profile of Norucholic acid (NCA) in primary sclerosing cholangitis (PSC) patients treated with NCA capsules within open-label-extension (OLE) NUC-5/PSC study (Satellite NUC-5/PSC study)
2019-000613-36DODEKAA phase I study to evaluate safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19.
2021-003999-14ALE100_Janssen A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
2022-003790-38LipOraPhase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra peptide in healthy volunteers
2021-000202-22MonumenTAL3A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination with Daratumumab SC (Tal-D) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd) 
2021-003380-95CDYP688A12101A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
2022-503133-54-00IMA402-PrameA Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients with Recurrent and/or Refractory Solid Tumors
2019-004046-16/2022-502684-37-00IMCF106C-101A Phase 1/2 First-in-Human Study of the Safety and
Efficacy of IMC-F106C as a Single Agent and in
Combination with Checkpoint Inhibitors in
HLA-A*02:01-Positive Participants with Advanced
PRAME-Positive Cancers
2022-003452-14BC 007/BLOCA prospective, double-blind, randomized, parallel group,
placebo-controlled, multicentre, Phase II study to investigate the efficacy,
GPCR autoantibody-neutralizing effect, safety, and tolerability of BC 007
in participants with long COVID
2022-502446-27MonumenTAL-6A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P),
Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either
Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and
Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to
4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
2023-506669-70DepleTTR-CMA Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the
Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin
Amyloid Cardiomyopathy (ATTR-CM)

 



Meist gesuchte Inhalte


DE